A5007229434- Pancreatic and Hepatic Oncology Research
- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Inflammatory Biomarkers in Disease Prognosis
- Lymphoma Diagnosis and Treatment
- Renal cell carcinoma treatment
- Viral-associated cancers and disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Pancreatitis Pathology and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Chronic Lymphocytic Leukemia Research
- Histiocytic Disorders and Treatments
- Cancer, Lipids, and Metabolism
- Neutropenia and Cancer Infections
- Esophageal Cancer Research and Treatment
- Histone Deacetylase Inhibitors Research
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Venous Thromboembolism Diagnosis and Management
- Hematological disorders and diagnostics
- Vascular Tumors and Angiosarcomas
- Blood disorders and treatments
- Sarcoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
Medical University of Vienna
2010-2024
Salzburger Landeskliniken
2013-2024
University of Salzburg
2024
Paracelsus Medical University
2014-2023
Cancer Research Institute of the Slovak Academy of Sciences
2020
Unfallkrankenhaus Salzburg
2020
Medical University of Graz
2011
Data on efficacy and safety of azacitidine in acute myeloid leukemia (AML) with >30 % bone marrow (BM) blasts are limited, the drug can only be used off-label these patients. We previously reported 155 AML patients treated within Austrian Azacitidine Registry (clinicaltrials.gov identifier NCT01595295). herein update this report a population almost twice as large (n = 302). This cohort included 172 BM blasts; 93 would have been excluded from pivotal AZA-001 trial (which led to European...
Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX are standard first-line treatment options for advanced pancreatic ductal adenocarcinoma (aPDAC), but currently no prospective randomised head-to-head comparison between these treatments has yet been performed.We conducted a comparative propensity score (PS) analysis of overall (OS) progression-free survival (PFS) in tri-centre cohort patients with aPDAC undergoing palliative either GN or FOLFIRINOX.In unadjusted analysis, OS PFS were highly...
Recent data suggest that azacitidine may be beneficial in CMML. We report on 48 CMML-patients treated with azacitidine. Overall response rates were high (70% according to IWG-criteria, including 22% complete responses). Monocyte count and cytogenetics adversely affected survival, whereas age, WHO-type, FAB-type, spleen size did not. Matched-pair analyses revealed a trend for higher two-year-survival as compared best supportive care (62% vs. 41%, p=0.067) longer OS first-line hydroxyurea...
High levels of C-reactive protein (CRP), an acute phase protein, proofed being associated with decreased clinical outcome in small-scale studies diffuse large B-cell lymphoma (DLBCL). The aim this study was to evaluate the prognostic impact pretreatment CRP on overall survival (OS) and disease-free (DFS) a bicentre DLBCL patients. Data from 477 patients, diagnosed treated between 2004 2013 at two Austrian centres, were evaluated retrospectively. influence other factors, including age, tumour...
We recently published a clinically-meaningful improvement in median overall survival (OS) for patients with acute myeloid leukaemia (AML), >30% bone marrow (BM) blasts and white blood cell (WBC) count ≤15 G/L, treated front-line azacitidine versus conventional care regimens within phase 3 clinical trial (AZA-AML-001; NCT01074047; registered: February 2010). As results obtained trials are facing increased pressure to be confirmed by real-world data, we aimed test whether data the...
Cytomegalovirus reactivation can be life threatening. However, little evidence on its incidence in solid cancers is available. Therefore our single center polymerase chain reaction database with altogether 890 CMV positive blood serum samples of mainly hematological and oncological patients was retrospectively analyzed to examine the occurrence tumors, resulting 107 tested for reactivation. Seventeen cancer a CMV-PCR test were identified, which eight had clinically relevant disease received...
The MDS-IWG and NCCN currently endorse both FAB WHO classifications of MDS AML, thus allowing patients with 20-30 % bone marrow blasts (AML20-30, formerly MDS-RAEB-t) to be categorised treated as either or AML. In addition, an artificial distinction between AML20-30 AML30+ was made by regulatory agencies initially restricting approval azacitidine AML20-30. Thus, uncertainty prevails regarding the diagnosis, prognosis optimal treatment timing strategy for Here, we aim provide clarification...
Background: Several serum parameters have been evaluated for adding prognostic value to clinical scoring systems in diffuse large B-cell lymphoma (DLBCL), but none of the reports used multivariate testing more than one parameter at a time. The goal this study was validate widely available their independent impact era National Comprehensive Cancer Network–International Prognostic Index (NCCN-IPI) score determine which were most useful. Patients and Methods: This retrospective bicenter...
Blood-based parameters are gaining increasing interest as potential prognostic biomarkers in patients with diffuse large B-cell lymphoma (DLBCL). The aim of this study was to comprehensively evaluate the significance pretreatment plasma uric acid levels newly diagnosed DLBCL. clinical course 539 DLBCL patients, and treated between 2004 2013 at two Austrian high-volume centres rituximab-based immunochemotherapy evaluated retrospectively. influence on overall survival (OS) progression-free...
Anemia is frequently identified at the time of diagnosis in patients with diffuse large B-cell lymphoma (DLBCL); however, studies addressing prognostic significance this important clinical parameter are lacking.In dual-center study DLBCL (n = 556) treated rituximab-containing regimens, we evaluated relevance anemia a training set 211) and validated our findings second independent patient cohort 345). Using Kaplan-Meier curves as well univariate multivariate Cox regression models, analyzed...
Histiocytic sarcoma (HS) is a rare but highly aggressive disease. The cancer-specific survival of patients with HS short and only limited response to conventional chemotherapy or radiation therapy seen. Some data from single case reports have suggested efficacy for high-dose autologous/allogeneic stem cell transplantation.We report on 4 cases HS, demonstrate that different druggable receptors are expressed HS. Using immunohistochemistry, we detected the expression platelet-derived growth...
Background Fibrinogen plays a crucial role in the pathophysiology of tumour cell growth, invasion and metastasis. The aim this study was to evaluate prognostic significance pretreatment plasma fibrinogen levels patients with diffuse large B lymphoma (DLBCL) Methods Data from 372 DLBCL, diagnosed treated between 2004 2013 at two Austrian centres, were evaluated retrospectively. influences other factors, including age, stage National Comprehensive Cancer Network-International Prognostic Index,...
: Background: Despite modern chemotherapy regimens, survival of patients with locally advanced/metastatic pancreatic cancer remains dismal. Long-term survivors are rare and there no prognostic scores to identify benefitting most from chemotherapy.This retrospective study includes 240 who were treated in a primary palliative setting between the years 2007 2016 single academic institution. Survival rates analyzed using Kaplan-Meier method. Prognostic models including laboratory clinical...
Introduction: The activity of butyrylcholinesterase (BChE) in blood reflects liver function and has recently been associated with systemic inflammatory response tumor cachexia. As these conditions have previously linked pancreatic cancer (PC), the purpose present study was to evaluate prognostic impact plasma BChE PC. Methods: Data from 574 consecutive PC patients, treated between 2004 2018 at a single academic center, evaluated. primary endpoint cancer-specific survival (CSS), analyzed by...
The advanced lung cancer inflammation index (ALI) was first introduced for prognosis prediction in patients and since then evaluated several other malignancies. However, pancreatic (PC) the ALI its prognostic utility were only investigated a comparably small specific cohort of locally PC treated with chemoradiotherapy.In our single-center study, we included 429 histologically verified who between 2003 2015 at academic institution. defined as body mass (BMI; kg/m2 ) × serum albumin levels...
Abstract Introduction Recent advances in prophylactic anticoagulation and antineoplastic treatment for advanced pancreatic cancer (aPC) warrant an updated reassessment of thromboembolic risk this population. This multicenter retrospective cohort study aims to comprehensively characterize incidence, factors, outcomes venous (VTE) arterial thromboembolism (ATE) homogenously treated patients with aPC. Methods Four hundred fifty-five aPC undergoing palliative first-line chemotherapy...
Despite modern chemotherapy regimens, survival of pancreatic cancer patients remains dismal. Toxicity is a major concern and it challenge to upfront identify with the highest benefit from aggressive polychemotherapy. We aimed evaluate ORR side effects FOLFIRINOX regimen, highlighting dose modification explore possible prognostic response factors as clinical tool.This retrospective study includes 123 metastatic PC that were treated between years 2007 2016 in single academic institution....
Background Platelets are a major cellular component of blood and their interaction with cancer cells is well-established to influence progression metastases. The physical size platelets may have critical impact on the cells. In this study, we explored potential prognostic role platelet measured by determination mean platetlet volume (MPV) in patients pancreatic ductal adenocarcinoma (PDAC). Methods Data from 527 PDAC diagnosed treated between 2004 2015 at single center were evaluated...
Perioperative chemotherapy with FLOT constitutes a standard of care approach for locally advanced, resectable gastric or gastro-esophageal junction (GEJ) cancer. We aimed at investigating anthropometric, CT-based and FDG-PET-based body composition parameters dynamics during this multidisciplinary the impact on clinical outcomes.This retrospective, single-center study was based medical records (FDG-PET)-CT images among gastric/GEJ cancer patients undergoing perioperative chemotherapy.Between...
Pancreatic carcinoma carries a devastating prognosis and is the 4th leading cause for cancer related death in US most European countries. Apart from imaging CA 19-9, pancreatic still lacking reliable markers to assess tumor dynamics monitor treatment response over time. The aim of this study was evaluate feasibility cell free tumor-DNA (cft-DNA), respectively KRAS mutation peripheral blood, detection as prognostic predictive value chemotherapy monitoring. Serial plasma samples 42 patients...
Abstract Background Pancreatic cancer is mostly diagnosed in an advanced stage and treated with systemic therapy palliative intent. Nowadays, the doublet chemotherapy of Gemcitabine nab‐paclitaxel (Gem‐Nab) one most frequently used regimens worldwide, but not ubiquitarily available or reimbursed. Therefore, we compared clinical efficacy Gem‐Nab to a historical control patients gemcitabine oxaliplatin (Gem‐Ox) at our tertiary center, which was standard treatment prior introduction FOLFIRINOX....